The Pharmacy Examining Board is created under
Wis. Stat. § 15.405(9), and has authority as outlined in
Wis. Stat. ch. 450.
The members of the Pharmacy Examining Board are appointed by the Governor and confirmed by the Legislature to serve 4-year terms. The Board consists of 5 licensed pharmacist members and 2 public members.
|Member||Officer||Member Type||Term Expiration|
|Schumacher, Thaddeus J.||Chairperson||Pharmacist Member||7/1/2019|
|Trapskin, Philip J.||Vice Chairperson||Pharmacist Member||7/1/2021|
|LaDien, Franklin (Rocky)||Secretary||Pharmacist Member||7/1/2020|
|Sullivan, Kristi||Public Member||7/1/2020|
|Weitekamp, John||||Pharmacist Member||7/1/2022|
|Winters, Cathy J.||Pharmacist Member||7/1/2021|
*Board members whose terms have expired may continue to serve until their successor is confirmed by the Senate.
U.S. Food and Drug Administration's lists of all currently approved interchangeable biological products.
The 2017 Quarter 4 ePDMP Report is now available.
2017 Quarter 4 e PDMP Report
Effective November 1, 2017, Phar 6 Has Been Updated Per 2017 Wisconsin Act 18
Phar 6 - Pharmacy Licenses and Equipment
2017 Wisconsin Act 18
Effective November 1, 2017, Phar 14 Has Been Updated
Phar 14 - Home Medical Oxygen Providers
Effective September 1, 2017, Phar 7.10 Has Been Updated
Phar 7.10 - Administration of drug products and devices other than vaccines
On October 1, 2016 the following Pharmacy Chapters were updated:
Phar 1, 8 Relating to Definitions and Controlled Substances
Phar 1, 2 and 4 Relating to Application and Examination
Phar 5 Relating to Renewal and Reinstatement
Phar 8 Relating to Identification Card Required for Certain Controlled Substances
2015 Act 313 went into effect on April 1, 2016. This Act no longer authorizes the Pharmacy Board to grant variances unless a disaster or emergency exists, but to instead institute
pilot projects. The Board is currently engaged in the transitioning of current non-emergency variances into pilot projects. Please see the link for more detailed information as to the Statutory requirements.
CSB 4.04(2)(p) goes into effect on April 9, 2017. This requires that the name recorded under
s. 450.11(1b)(bm), Stats. be submitted to the Prescription Drug Monitoring Program.
2015 Act 291 relating to prescription fills and refills went into effect on April 1, 2016.
Please review the following update:
NTSB Information on Risk of Pilot Impairment
As of September 1, 2014,
Phar 8.05(4), 8.07(2) and
8.09 were amended to allow electronic prescriptions for
schedule II controlled substances.
On August 28, 2014 the DEA published its final rule in the Federal Register placing Suvorexant into Schedule IV of the Federal Controlled Substances Act. The scheduling action was effective September 29, 2014. The Wisconsin Controlled Substances Board pursuant to s. 961.11(4), Stats took affirmative action to treat
Suvorexant as a Schedule IV effective November 1, 2014.
On August 22, 2014 the DEA published its final rule in the Federal Register rescheduling hydrocodone combination products from Schedule III to Schedule II of the Federal Controlled Substances Act. The scheduling action was effective October 6, 2014. The Wisconsin Controlled Substances Board pursuant to s. 961.11(4), Stats took affirmative action to similarly
reschedule hydrocodone combination products from Schedule III to Schedule II effective November 1, 2014.
On July 2, 2014, the DEA published its final rule in the Federal Register placing tramadol into schedule IV of the federal Controlled Substances Act effective August 18, 2014. The Wisconsin Controlled Substances Board pursuant to s. 961.11(4), Stats took affirmative action to similarly treat tramadol as a
schedule IV controlled substance effective September 1, 2014.
As of November 1, 2013,
Phar 7.01(1)(e), Wis. Admin. Code, relating to delivery, became effective.
Last updated: 1/2/2019